KM12 Xenograft Model Service for Colon Cancer

The KM12 Xenograft Model Service for Colon Cancer provides a robust, validated platform for evaluating therapeutic efficacy against BRAF V600E-mutant and TPM3-NTRK1 fusion-driven colorectal adenocarcinoma in vivo. Alfa Cytology leverages this clinically relevant cell line to deliver reproducible preclinical data, supporting your drug development pipeline from lead optimization to combination strategy assessment.

Overview of KM12 Xenograft Model for Colon Cancer

KM12 is a human colorectal adenocarcinoma cell line originally established from a Dukes B2 stage primary tumor. It harbors a BRAF V600E activating mutation and a rare TPM3-NTRK1 gene fusion, resulting in constitutive TRKA kinase activation and MAPK pathway hyperactivity. The cell line is near-diploid with a doubling time of approximately 23.7 hours and exhibits microsatellite instability (MSI) status. In xenograft systems, KM12 demonstrates reliable tumorigenicity with consistent tumor take rates, forming well-circumscribed subcutaneous tumors that enable high-throughput pharmacological screening. Its defined molecular profile makes it particularly valuable for evaluating targeted agents such as BRAF/MEK inhibitors, TRK inhibitors, and combination regimens addressing adaptive resistance.

Preclinical studies utilizing KM12 xenografts have established this model as a cornerstone for investigating NTRK fusion-positive colorectal cancer. The TPM3-NTRK1 fusion renders KM12 highly sensitive to pan-TRK inhibitors including entrectinib, merestinib, and next-generation compounds such as zurletrectinib. Additionally, the model has been instrumental in characterizing oxaliplatin resistance mechanisms and evaluating cetuximab-mediated sensitization through EGFR pathway modulation. KM12 xenografts support both standard subcutaneous implantation and advanced imaging applications, including [18F]TRACK PET tracer studies for quantifying TRKA activity in vivo, providing a versatile platform for translational colorectal cancer research.

Figure 1. Meta-analysis of proteomics data of liver metastatic KM12SM in comparison to parental non-metastatic KM12C CRC cells. (Montero-Calle, Ana, et al., 2022)

Cell Line Information: KM12

The following table summarizes the key biological and molecular characteristics of the KM12 cell line, providing essential reference data for experimental design and data interpretation in xenograft studies.

Our Services

Alfa Cytology provides end-to-end KM12 xenograft model services tailored to your preclinical research objectives. Our platform integrates rigorous cell line authentication, standardized tumor implantation protocols, and comprehensive endpoint analyses---including tumor growth kinetics, pharmacodynamic biomarker profiling, histopathology, and molecular characterization---to deliver publication-ready data packages that accelerate your therapeutic development timeline.

Workflow of KM12 Xenograft Model Construction

Alfa Cytology follows a standardized, IACUC-guided workflow to construct KM12 xenograft models, ensuring reproducible tumor growth and reliable therapeutic evaluation. The process spans from cell preparation through endpoint analysis, with quality checkpoints at each stage to maintain model integrity and data validity.

1. Cell Culture Expansion and Quality Control: KM12 cells are maintained in RPMI 1640 with 5% FBS and expanded during exponential growth phase. Cells are harvested prior to 80% confluence and passaged no more than 20 times to preserve genetic fidelity. Mycoplasma testing and STR authentication are performed to confirm cell line identity and purity.
2. Cell Viability Assessment and Preparation: Harvested cells are washed with PBS and resuspended in fresh serum-free medium. Viability is determined by trypan blue exclusion, with a minimum threshold of 98% viable cells required for implantation. The cell suspension is concentrated to the appropriate density and mixed with Matrigel on ice to enhance engraftment efficiency.
3. Animal Preparation and Subcutaneous Implantation: Immunodeficient mice (athymic nude BALB/c or NOD/SCID, 10-12 weeks old) are acclimatized for a minimum of five days. Each mouse receives a single subcutaneous injection of 1 × 10^6 KM12 cells in 100-200 µL Matrigel suspension into the flank. Injection sites are palpated weekly to monitor tumor establishment.
4. Tumor Monitoring and Randomization: Tumor dimensions are measured by digital calipers twice weekly. Tumor volume is calculated using the modified ellipsoid formula: V = (length x width^2) / 2. Once tumors reach a mean volume of 50-150 mm^3, mice are randomized into treatment cohorts based on tumor size and body weight to minimize inter-group variability.
5. Treatment Administration and In-Life Monitoring: Test compounds are administered according to the predefined dosing schedule via the specified route (oral gavage, intravenous, intraperitoneal, or intratumoral). Body weights and clinical signs are recorded up to three times weekly. Tumor measurements continue on a defined schedule to capture growth inhibition or regression dynamics.
6. Pharmacodynamic and Biomarker Sampling: Optional interim blood collections and tumor biopsies are performed under anesthesia for pharmacokinetic/pharmacodynamic correlation. Plasma drug concentrations, blood chemistry panels, and tumor tissue biomarkers (phosphorylated ERK, AKT, Ki-67) are analyzed to establish mechanism-of-action evidence.
7. Endpoint Analysis and Necropsy: Studies are terminated when tumors reach the predetermined size limit (typically 2,000 mm^3) or at the protocol-defined study end. Mice are humanely euthanized, and tumors are excised, weighed, and documented. Tissues are processed for histopathology (H&E, IHC), snap-frozen in liquid nitrogen for molecular analysis, or fixed in formalin for archival storage.

Figure 2: Schematic workflow illustrating the derivation and construction of the KM12 Xenograft Model at Alfa Cytology.

Case Study-KM12 Xenograft Model Development

In a representative KM12 xenograft development study, immunodeficient mice were implanted subcutaneously with 1 × 10^6 KM12 cells in Matrigel. Tumors became palpable within 7-10 days and reached the randomization threshold of 50-150 mm^3 by day 14-18 post-implantation. Treatment cohorts received either vehicle control, monotherapy, or combination regimens according to the study design. Tumor growth curves demonstrated consistent kinetics across replicate studies, with vehicle-treated tumors exhibiting exponential growth reaching endpoint volumes within 3-4 weeks. Pharmacodynamic analysis of tumor lysates confirmed target engagement through modulation of phosphorylated ERK and TRKA signaling pathways. Histopathological evaluation revealed dose-dependent reductions in Ki-67 proliferation index and increased apoptotic bodies in active treatment groups. Complete dataset, statistical analysis, and raw data are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology delivers scientifically rigorous, operationally efficient KM12 xenograft services designed to meet the demands of modern preclinical oncology research. Our integrated platform combines validated models with comprehensive analytical capabilities to generate decision-enabling data.

• Validated cell line authentication and mycoplasma screening ensure model integrity from initiation to endpoint.
• Standardized tumor implantation protocols with documented take rates exceeding 95% across replicate studies.
• Flexible study designs accommodating monotherapy, combination therapy, dose-response, and scheduling optimization.
• Comprehensive pharmacodynamic profiling including p-ERK, p-AKT, Ki-67, and custom biomarker development.
• GLP-compliant data packages with detailed methods, statistical analysis, and raw data suitable for regulatory submissions.
• Rapid study initiation with dedicated project management and weekly progress reporting.
• Custom endpoint analysis including histopathology, immunohistochemistry, RNA/protein extraction, and gene expression profiling.

Contact Us

To discuss your KM12 colon cancer xenograft study requirements, receive a customized proposal, or access our confidential preclinical dataset, please reach out to us or reach out to our scientific team. We are committed to accelerating your therapeutic development program with reliable, data-driven preclinical insights.

For research use only. Not intended for any clinical use.